Spyre Therapeutics (SYRE)
Develops extended-half-life antibody combinations for bowel, rheumatic, and dermatologic diseases.
$87.36
vs last close−4.61 (−5.01%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 107.30% | 94.61M shares | |
|---|---|---|---|
| 276 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.81% | 713.1K shares | |
| 5 holders · as of Sep 3, 2026 | |||
| Adds to | 108.11% | ||
88.17M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 108.11%; nothing is left for Other.
13F, as of Jun 30, 2026
276 holders · 94.61M shares · 93 new positions · 198 increased · 56 reduced · 23 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 13.03M | 14.77% | +1.25M | Aug 13, 2026 |
| BlackRock, Inc. | 6.51M | 7.38% | +985.4K | Aug 7, 2026 |
| Perceptive Advisors LLC | 4.32M | 4.90% | +536.3K | Aug 14, 2026 |
| RTW Investments, LP | 4.25M | 4.82% | +80.0K | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 3.84M | 4.36% | +1.88M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 3.45M | 3.91% | +391.3K | Aug 13, 2026 |
| State Street Corp | 3.06M | 3.47% | +450.4K | Aug 7, 2026 |
| VR Adviser, LLC | 2.99M | 3.39% | −700.0K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Tomas Kiselakincl. Fairmount Healthcare Fund II L.P., Peter Evan Harwin +1 more | 9.99% | 9.67M | 13D | Jun 23, 2026 |
| Peter E. Deutsch | 6.99% | 3.55M | 13G | Oct 23, 2024 |
| BlackRock, Inc. | 6.60% | 3.96M | 13G | Jul 16, 2025 |
| RTW Investments, LP | 6.20% | 3.62M | 13G | Feb 14, 2025 |
| Perceptive Advisors LLC | 5.00% | 4.32M | 13G | Apr 22, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 1, 2026 | Cameron Turtledirector, officer: Chief Executive Officer | Sale · 4 lots | 15,000 | $87.29 | 552,540 |
| Sep 2, 2026 | Scott L. Burrowsofficer: Chief Financial Officer | Sale | 18,232 | $89.35 | 79,762 |
| Sep 1, 2026 | Scott L. Burrowsofficer: Chief Financial Officer | Sale · 4 lots | 7,500 | $87.31 | 97,994 |
| Sep 2, 2026 | Heidy King-Jonesofficer: See Remarks | Sale | 400 | $90.00 | 2,845 |
| Sep 1, 2026 | Heidy King-Jonesofficer: See Remarks | Sale · 4 lots | 27,999 | $87.31 | 2,845 |
| Aug 7, 2026 | Jeffrey W. Albersdirector | Sale · 3 lots | 23,000 | $104.53 | 9,360 |
| Aug 3, 2026 | Cameron Turtledirector, officer: Chief Executive Officer | Sale · 5 lots | 15,000 | $95.51 | 567,540 |
| Aug 3, 2026 | Scott L. Burrowsofficer: Chief Financial Officer | Sale · 3 lots | 7,500 | $95.57 | 97,994 |
| Jul 1, 2026 | Cameron Turtledirector, officer: Chief Executive Officer | Sale · 3 lots | 15,000 | $87.69 | 582,540 |
| Jul 1, 2026 | Sheldon Sloanofficer: Chief Medical Officer | Sale · 2 lots | 8,334 | $87.70 | 0 |
House and Senate disclosures
Not reported.